Novartis International Pharmaceutical Limited – Trademark Portfolio

Entity Type: 03

Novartis International Pharmaceutical Limited holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include DENAVIR. The owner is based in Summit, NJ.

564 Morris Avenue

Summit, NJ 07901

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

DENAVIR
DENAVIR
Registered 1996

Trademark Classifications

Novartis International Pharmaceutical Limited's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Novartis International Pharmaceutical Limited have?

Novartis International Pharmaceutical Limited has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Novartis International Pharmaceutical Limited file in?

Novartis International Pharmaceutical Limited files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Novartis International Pharmaceutical Limited's most well-known trademarks?

Novartis International Pharmaceutical Limited's registered trademark portfolio includes well-known marks such as DENAVIR. These are among 1 currently registered trademark in the portfolio.

What is Novartis International Pharmaceutical Limited's trademark registration success rate?

Novartis International Pharmaceutical Limited has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.